Susquehanna International Group, LLP Entera Bio Ltd. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.05 $700 - $1,470	-1,400 Reduced 2.66%	51,300 $37,000
Q3 2022 Nov 14, 2022	SELL	$0.07 - $1.98 $63 - $1,782	-900 Reduced 1.68%	52,700 $55,000
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.95 $3,192 - $7,080	-2,400 Reduced 4.29%	53,600 $71,000
Q1 2022 May 16, 2022	SELL	$1.91 - $3.23 $17,381 - $29,393	-9,100 Reduced 13.98%	56,000 $160,000
Q4 2021 Feb 14, 2022	SELL	$2.82 - $4.79 $69,936 - $118,792	-24,800 Reduced 27.59%	65,100 $184,000
Q3 2021 Nov 15, 2021	SELL	$4.43 - $6.29 $274,660 - $389,980	-62,000 Reduced 40.82%	89,900 $423,000
Q2 2021 Aug 11, 2021	BUY	$2.92 - $6.5 $443,548 - $987,350	151,900 New	151,900 $908,000

5.34M

2.6K

100

Ticker ENTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,809,900
Market Cap $49.8M
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.